Question-and-Answer Session
Operator
(Operator Instruction) You have your first question comes from the line of Allan Corn.
Allan Corn – Unidentified Company
On your diabetic drug.
Arthur Sands
Well I didn’t hear that, something about drugs, the diabetic drug. Okay, go ahead.
Allan Corn – Unidentified Company
How soon do you think will be available for use, where you have a large trial.
Arthur Sands
Well its one step at a time, lets put it that way. I think what we are willing to forecast at this point is that we’ll get results from our first in-patient trial in the first quarter, which is a big step forward for a new entity, and then we’ll make the judgment call based on the data. So that’s about all we can say at this time.
I’ll put it in context though, that’s fairly rapid for the phase 2a program, because we did compress it by doing a trial a four way trial in patients, these are patients that are sequestered in the units that we are monitoring everything, and so I think in a very reasonable time frame we’ll get those results.
Allan Corn – Unidentified Company
Thank you
Arthur Sands
Thank you.
Operator
(Operator Instruction) And there are no further questions. I would now like to turn the call over to Dr. Sands.
Arthur Sands
Well thank you. I anticipate over the next twelve months that we’ll have a lot of questions, and I think that’s true because that’s of course the time frame in which we’ll have these results. We are on stage now to evaluate those, and I’m referring to the slides that have the timeline over the next twelve months for these four trials which we spend a fair amount of time now reviving. So we look forward to keeping you updated as the results flow in, and thank you for you participation. Bye-bye.
Operator
This concludes today’s conference call. You may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
- To read the full transcript on Seeking Alpha, click here »
